On April 20, 2018 Varian (NYSE: VAR) reported it has received FDA 510(k) clearance for its Calypso Anchored Beacon transponder. Used with a Varian TrueBeam, Edge and Clinac C-series medical linear accelerators, the Calypso system and Anchored Beacon transponder detects even slight movements of a tumor and helps clinicians deliver lung stereotactic body radiotherapy (SBRT) more precisely (Press release, Varian Medical Systems, APR 20, 2018, View Source [SID1234525563]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Calypso system works by implanting the Anchored Beacon transponders in small airways within or near the tumor target. The Anchored Beacon transponders feature five small "legs" that provide stable fixation to prevent the transponder from moving. The transponders emit non-ionizing electromagnetic signals that are tracked in real-time and used to keep a treatment beam on target.

The Calypso System is the only device on the market that delivers real-time, continuous (25 Hz update rate), 3D tumor position information, improving confidence that the prescribed dose has been delivered to the tumor.

"The 510(k) clearance of the Anchored Beacon transponder expands the application of the Calypso system platform," said Ed Vertatschitsch, vice president, Global Portfolio Solutions, Varian. "Using the Calypso system and Anchored Beacon transponder, clinicians can deliver dose to lung tumors with increased confidence and accuracy."

For more information on the Calypso system, visit www.varian.com/calypso.